References

vtio

Вестник трансплантологии и искусственных органов

Russian Journal of Transplantology and Artificial Organs

1995-1191

Academician V.I.Shumakov National Medical Research Center of Transplantology and Artificial Organs", Ministry of Health of the Russian Federation

10.15825/1995-1191-2009-2-67-74

vtio-235

Research Article

Обзор литературы

Literature Reviews

ТРАНСПЛАНТАЦИЯ КЛЕТОК КОСТНОГО МОЗГА И ПУПОВИННОЙ КРОВИ КАК СПОСОБ КОРРЕКЦИИ АУТОИММУННЫХ МЕХАНИЗМОВ РАЗВИТИЯ САХАРНОГО ДИАБЕТА I ТИПА

TRANSPLANTATION OF BONE MARROW CELLS AND UMBILICAL CORD BLOOD CELLS AS A WAY FOR CORRECTION OF AUTOIMMUNE MECHANISMS IN DEVELOPMENT OF DIABETES MELLITUS TYPE I

Великий

Д. А.

Velikiy

D. A.

Закирьянов

А. Р.

Zakirianov

A. R.

Поздняков

О. М.

Pozdnyakov

O. M.

Онищенко

Н. А.

Onischenko

N. A.

illak@mail.ru

ФГУ «Федеральный научный центр трансплантологии и искусственных органов имени академика В.И. Шумакова» Минздравсоцразвития РФ, МоскваРоссияAcademician V.I. Shumakov Federal Research Center of Transplantology and Artificial Organs, MoscowRussian Federation

ФГУ «НИИ общей патологии и патофизиологии РАМН», МоскваРоссияResearch Institute of General Pathology and Pathophysiology RAMS, MoscowRussian Federation

2009

30052014

1126774

2009

Великий Д.А., Закирьянов А.Р., Поздняков О.М., Онищенко Н.А.

Velikiy D.A., Zakirianov A.R., Pozdnyakov O.M., Onischenko N.A.

Данная работа распространяется под лицензией Creative Commons Attribution 4.0.

This work is licensed under a Creative Commons Attribution 4.0 License.

https://journal.transpl.ru/vtio/article/view/235

В обзоре представлена современная концепция развития аутоиммунного сахарного диабета. Рассмот- рена возможность коррекции иммунных нарушений и регенерации β-клеток путем трансплантации клеток костного мозга и пуповинной крови.

In this review the modern conception of development of autoimmune diabetes mellitus was presented. Possibilities of immune disturbances correction and β-cells regeneration at transplantation of bone marrow and umbilical cord blood cells were considered.

аутоиммунный сахарный диабетклетки костного мозгарегенерация

autoimmune diabetes mellitusbone marrow cellsregeneration

References1

Аскаров М.Б., Онищенко Н.А., Макарова О.В. Восста- новление морфофункционального состояния орга- нов иммуногенеза и течение длительно незаживаю- щих аутоиммунных язв желудка при трансплантации культивированных клеток аутогенного костного моз- га // Клеточная трансплант. и тканевая инженерия. 2008. V. 3. P. 36–42.

Бабаева А.Г. Роль иммунной системы в дизрегуляции морфогенетических процессов // Дизрегуляционная патология; под ред. Г.Н. Крыжановского. М.: Меди- цина, 2002. С. 366–385.

Галактионов В.Г. Эволюционная иммунология. М.: Академкнига, 2005. 408 с.

Гольдберг Е.Д., Дыгай А.М., Жданов В.В. и др. Со- стояние пулов стволовых клеток при эксперимен- тальном сахарном диабете // Клеточные технологии в биологии и медицине. 2006. V. 3. P. 123–127.

Дедов И.И., Балаболкин М.И., Клебанова Е.М., Кре- минская В.М., Чазова Т.Е. Сахарный диабет: пато- генез, классификация, диагностика и лечение. М., 2003. 171 с.

Делягин В.М., Волков И.Э., Румянцев А.Г., Скурко- вич С.В. Иммунные и неиммунные нарушения при сахарном диабете типа 1 у детей // Вопросы гемато- логии / онкологии и иммунопатологии в педиатрии. 2004. V. 3 (2). P. 76–80.

Закирьянов А.Р., Онищенко Н.А., Клименко Е.Д., Поз- дняков О.М. Регенерационная клеточная терапия са- харного диабета I типа и его осложнений // Вестник РАМН. 2008. V. 3. P. 42–51.

Темнов А.А. Клеточная трансплантация при лече- нии хронической сердечной недостаточности: Дис. ... д-ра мед. наук. М., 2008.

Abdi R., Fiorina P., Adra C.N., Atkinson M., Sayegh M.H. Immunomodulation by mesenchymal stem cells: a potential therapeutic strategy for type 1 diabetes // Diabetes. 2008. V. 57. P1759–1767.

Aggarwal S., Pittenger M.F. Human mesenchymal stem cells modulate allogenetic immune cell responses // Blood. 2005. V. 105. P. 1815–1822.

Alvarez-Dolado M. Cell fusion: biological perspectives and potential for regenerative medicine // Front Biosci. 2007. V. 12. P. 1–12.

Arthur A., Zannettino A., Gronthos S. The therapeutic applications of multipotential mesenchymal/stromal stem cells in skeletal tissue repair // J Cell Physiol. 2009. V. 218 (2). P. 237–245.

Banerjee M., Kumar A., Bhonde R.R. Reversal of ex- perimental diabetes by multiple bone marrow trans- plantation // Biochem. Biophys. Res. Commun. 2005. V. 328 (1). P. 318–325.

Boumaza I., Srinivasan S., Witt W.T., Feghali-Bost- wick C., Dai Y., Garcia-Ocana A., Feili-Hariri M. Auto- logous bone marrow-derived rat mesenchymal stem cells promote PDX-1 and insulin expression in the islets, alter T-cell cytokine pattern and preserve regulatory T-cells in the periphery and induce sustained normoglycemia // J Autoimmun. 2008 Dec 3. [Epub ahead of print].

Corcione A., Benvenuto F., Ferretti E. et al. Human mesenchymal stem cells modulate B-cell functions // Blood. 2006. V. 107. P. 367–372.

Dazzi F., van Laar J.M., Cope1 A., Tyndall A. Cell thera- py for autoimmune diseases. Arthritis Research & Ther- apy. 2007. V. 9. P. 206.

de Kleer I., Vastert B., Klein M., Teklenburg G. et al. Autologous stem cell transplantation for autoimmunity induces immunologic self-tolerance by reprogramming autoreactive T-cells and restoring the CD4+CD25+ immune regulatory network // Blood. 2006. V. 107. P. 1696–1702.

Haller M.J., Viener H., Wasserfall C. et al. Autologous umbilical cord blood infusion for type 1 diabetes // Ex- perimental Hematology. 2008. V. 36. P. 710–715.

Hess D., Li L., Martin M. et al. Bone marrow-derived stem cells initiate pancreatic regeneration. Nat. Biotech- nol. 2003. V. 21 (7). P. 763–770.

Homo-Delarche F., Drexhage H.A. Immune cells, pan- creas development, regeneration and type 1 diabetes. Trends Immunol. 2004. V. 25 (5). P. 222–229.

Izumida Y., Aoki T., Yasuda D. et al. Hepatocyte growth factor is constitutively produced by donor-derived bone marrow cells and promotes regeneration of pancreatic beta-cells // Biochem. Biophys. Res. Commun. 2005. V. 333 (1). P. 273–282.

Jahromi M.M., Eisenbarth G.S. Genetic determinants of type 1 diabetes across populations // Ann. N.Y. Acad. Sci. 2006. V. 1079. P. 289–299.

Kayali A.G., Van Gunt K., Campbell I., Stotland A., Krit- zik M., Liu G. et al. The stromal cell-derived factor-1al- pha/CXCR4 ligand-receptor axis is critical for progeni- tor survival and migration in the pancreas // J Cell Biol. 2003. V. 163. P. 859–869.

Koblas T., Harman S.M., Saudek F. The application of umbilical cord blood cells in the treatment of diabetes mellitus // Rev Diabet Stud. 2005. V. 2. P. 228–234.

Lammert E., Cleaver O., Melton D. Induction of pan- creatic differentiation by signals from blood vessels // Science. 2001. V. 294 (5542). P. 564–567.

Lee R.H., Seo M.J., Reger R.L. et al. Multipotent stro- mal cells from human marrow home to and promote re- pair of pancreatic islets and renal glomeruli in diabetic NOD/scid mice // Proc. Natl. Acad. Sci. USA. 2006. V. 103 (46). P. 17438–17443.

Lindley S., Dayan C.M., Bishop A., Roep B.O., Peak- man M., Tree T.I. Defective suppressor function in CD4+ CD25+ T-cells from patients with type 1 diabetes // Dia- betes. 2005. V. 54. P. 92–99.

Loomans C.J., de Koning E.J., Staal F.J. et al. Endothe- lial progenitor cell dysfunction: a novel concept in the pathogenesis of vascular complications of type 1 diabe- tes // Diabetes. 2004. V. 53 (1). P. 195–199.

Lundsgaard D., Holm T.L., Hornum L., Markholst H. In vivo control of diabetogenic T-cells by regulatory CD4+CD25+ T-cells expressing Foxp3 // Diabetes. 2005. V. 54. P. 1040–1047.

Peng Y., Laouar Y., Li M.O., Green E.A., Flavell R.A. TGF-b regulates in vivo expansion of Foxp3-expressing CD4+ CD25+ regulatory T-cells responsible for protec- tion against diabetes // Proc. Natl. Acad. Sci. USA. 2004. V. 101. P. 4572–4577.

Rabinovitch A., Suarez-Pinzon W.L. Role of cytokines in the pathogenesis of autoimmune diabetes mellitus // Rev. Endocr. Metab. Disord. 2003. V. 4 (3). P. 291–299.

Randolph D.A., Fathman C.G. CD4+CD25+ regulatory T-cells and their therapeutic potential // Annu Rev Med. 2006. V. 57. P. 381–402.

Ringden O., Uzunel M., Rasmusson I. et al. Mesen- chymal stem cells for treatment of therapy-resistant graft-versus-host disease. Transplantation. 2006. V. 81. P. 1390–1397.

Rosenzweig A. Cardiac cell therapy – mixed results from mixed cells // Engl J Med. 2006. V. 355. P. 1274– 1277.

Sakaguchi S. Naturally arising CD4+ regulatory T-cells for immunologic self-tolerance and negative control of immune responses // Annu Rev Immunol. 2004. V. 22. P. 531–562.

Selmani Z., Naji A., Zidi I., Favier B., Gaiffe E. et al. Human leukocyte antigen-G5 secretion by human me- senchymal stem cells is required to suppress T-lymp- hocyte and natural killer function and to induce CD4+ CD25high Foxp3+ regulatory T-cells // Stem Cells. 2008. V. 26. P. 212–222.

Sia C., Homo-Delarche F. Tolerance Induction and En- dogenous Regeneration of Pancreatic β-cells in Estab- lished Autoimmune Diabetes. Rev. Diabetic Stud. 2004. V. 1. P. 198–206.

Sotiropoulou P.A., Perez S.A., Gritzapis A.D., Baxeva- nis C.N., Papamichail M. Interactions between human mesenchymal stem cells and natural killer cells // Stem Cells. 2006. V. 24. P. 74–85.

Tarbell K.V., Petit L., Zuo X., Toy P. et al. Dendritic cell- expanded, islet-specific CD4+ CD25+ CD62L+ regu- latory T-cells restore normoglycemia in diabetic NOD mice // J. Exp. Med. 2007. V. 204 (1). P. 191–201.

Uccelli A., Pistoia V., Moretta L. Mesenchymal stem cells: a new strategy for immunosuppression? // Trends Immunol. 2007. V. 28. P. 219–226.

van der Vliet H.J., Nieuwenhuis E.E. IPEX as a result of mutations in Foxp3 // Clin Dev Immunol. 2007. P. 89017.

Vanikar A.V., Modi P.R., Patel R.D. et al. Hematopoi- etic stem cell transplantation in autoimmune diseases:the Ahmedabad experience // Transplant. Proc. 2007.

V. 39 (3). P. 703–708.

Voltarelli J.C., Couri C.E., Stracieri A.B. et al. Autolo-

gous nonmyeloablative hematopoietic stem cell trans- plantation in newly diagnosed type 1 diabetes mellitus // JAMA. 2007. V. 297. P. 1568–1576.

von Herrath M., Homann D. Islet regeneration needed for overcoming autoimmune destruction – considerati- ons on the pathogenesis of type 1 diabetes // Pediatr Di- abetes. 2004. V. 5 (Suppl. 2). P. 23–28.

Waldmann H., Chen T.C., Graca L., Adams E. et al. Re- gulatory T-cells in transplantation // Semin Immunol. 2006. V. 18. P. 111–119.

Wild S., Roglic G., Green A., Sicree R., King H. Global prevalence of diabetes // Diabetes Care. 2004. V. 27. P. 1047–1053.

Winter W.E., Harris N., Schatz D. Immunological markers in the diagnosis and prediction of autoimmu- ne type 1a diabetes // Clinical Diabetes. 2002. V. 20. P. 183–191.

Yamazaki S., Bonito A.J., Spisek R., Dhodapkar M.V. et al. Dendritic cells are specialized accessory cells along with TGF-b for the differentiation of Foxp3+ CD4+ regula- tory T cells from peripheral Foxp3-precursors //Blood. 2007. V. 110. P. 4293–4302.

Yoon J.W., Jun H.S. Autoimmune destruction of pancre- atic beta cells // Am. J. of Therapeutics. 2005. V. 12 (6). P. 580–591.

Zhang W., Ge W., Li C., You S., Liao L. et al. Effects of mesenchymal stem cells on differentiation, matura- tion, and function of human monocyte-derived dendritic cells // Stem Cells Dev. 2004. V. 13. P. 263–271.

The authors declare that there are no conflicts of interest present.